Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B

This article was originally published in The Pink Sheet Daily

Executive Summary

News on melanoma could put the biotech’s lucrative partnership with GlaxoSmithKline in jeopardy.

You may also be interested in...



How A Biomarker Revived Synta’s Cancer Drug Elesclomol

Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.

How A Biomarker Revived Synta’s Cancer Drug Elesclomol

Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.

Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data

ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel